A turning point in hepatology? EASL reflects on the first approved drug for MASH.

Francque, Sven; Krag, Aleksander; Shawcross, Debbie L; Zelber-Sagi, Shira

Francque, Sven; Krag, Aleksander; Shawcross, Debbie L; Zelber-Sagi, Shira.

Afiliación

Francque S; Department of Gastroenterology Hepatology, Antwerp University Hospital, Edegem, Belgium; InflaMed Centre of Excellence, Laboratory for Experimental Medicine and Paediatrics, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk
Krag A; Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: Aleksander.Krag@rsyd.dk.
Shawcross DL; Institute of Liver Studies, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, UK.
Zelber-Sagi S; School of Public Health, University of Haifa, Haifa, Israel.

J Hepatol ; 81(2): 192-194, 2024 Aug.

Article en En | MEDLINE | ID: mdl-38762170

Asunto(s)

Aprobación de Drogas; Gastroenterología; Humanos; Gastroenterología/métodos; Europa (Continente); Anticuerpos Monoclonales Humanizados/uso terapéutico

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aprobación de Drogas / Gastroenterología Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google